MINI REVIEW

Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation

Luca Marchetti and Britta Engelhardt
Theodor Kocher Institute, University of Bern, Bern, Switzerland
Correspondence should be addressed to B Engelhardt: bengel@tki.unibe.ch

Abstract
To maintain the homeostatic environment required for proper function of CNS neurons the endothelial cells of CNS microvessels tightly regulate the movement of ions and molecules between the blood and the CNS. The unique properties of these blood vascular endothelial cells are termed blood-brain barrier (BBB) and extend to regulating immune cell trafficking into the immune privileged CNS during health and disease. In general, extravasation of circulating immune cells is a multi-step process regulated by the sequential interaction of adhesion and signalling molecules between the endothelial cells and the immune cells. Accounting for the unique barrier properties of CNS microvessels, immune cell migration across the BBB is distinct and characterized by several adaptations. Here we describe the mechanisms that regulate immune cell trafficking across the BBB during immune surveillance and neuroinflammation, with a focus on the current state-of-the-art in vitro and in vivo imaging observations.

Multi-step immune cell migration across the vascular wall: an introduction
A glossary of immunology terms is presented in Table 1 for better understanding of this review.

Extravasation of circulating immune cells across the vascular wall is a multi-step process characterized by the sequential interaction of adhesion and signalling molecules on the vascular endothelial and immune cells. Pioneering in vivo and in vitro live cell imaging studies of the Butcher and Springer laboratories have already established in the early 1990s that immune cells as diverse as naïve lymphocytes and neutrophils use a multi-step extravasation process to leave the blood stream specifically in postcapillary venules reaching lymph nodes and inflamed tissues, respectively (1, 2). Live cell imaging has allowed to visualize that in postcapillary venules immune cells marginate and after an initial tether or capture, roll along the endothelial cell surface, a process mediated by selectins and their respective carbohydrate ligands (1). Rolling reduces the speed of the immune cells allowing for their subsequent recognition of chemokines immobilized on proteoglycans on the surface of endothelial cells with their G-protein-coupled receptors (GPCRs) (reviewed in (3)). GPCR activation triggers inside-out-activation of immune cell integrins, inducing profound conformational changes that ultimately result in a transition from low to a high affinity status of the individual integrins in addition to integrin clustering increasing integrin avidity (4). Activated integrins enable firm arrest of the immune cells on the luminal surface.
of the endothelial cells by engagement of endothelial adhesion molecules from the immunoglobulin superfamily (IgCAMs). Subsequent polarization and crawling on the luminal side of the endothelium allows the immune cells to find the endothelial junctions, which allow for their diapedesis across the endothelial barrier (reviewed in (3)). Before reaching the tissue parenchyma, immune cells have to cross the endothelial basement membrane, a dense network of extracellular matrix proteins, which establishes an additional barrier for their passage (reviewed in (3)).

The CNS is an immune privileged organ where the endothelial, epithelial and glial brain barriers strictly control immune cell entry into the different compartments of the CNS (5). Major differences in cellular composition, vessel and barrier characteristics between the peripheral and CNS vasculature are summarized in Table 2. Immune cells can reach the CNS via three different entry sites: via CNS parenchymal and leptomeningeal microvessels, and via the choroid plexus (6). Here we will focus on discussing our current knowledge on immune cell trafficking across the blood-brain barrier (BBB).

### The blood-brain barrier

The BBB is a physical and functional barrier present at the level of the CNS microvasculature. Originally the unique biochemical characteristics of BBB endothelial cells including complex tight junctions (TJs) between the endothelial cells and polarized expression of specific transporters and efflux pumps were considered restricted to capillaries. However, recent studies have provided evidence that the unique physical and metabolic barrier characteristics extend to the endothelial cells of CNS postcapillary venules (7, 8). Therefore we and others have extended referring to this vascular segment as BBB (9), as these characteristics impact on immune cell trafficking into the CNS (7, 10, 11).

Structurally, the BBB is localized at the level of the highly specialized endothelial cells, which exert most of
The complex network of AJs and TJs, together with the low pinocytotic activity, the lack of fenestrated cells, and the expression of specific sets of efflux pumps and nutrient transporters in BBB endothelial cells, results in a semipermeable barrier that contributes to the maintenance of the brain's microenvironment.

Table 2: Comparison between cellular components and vessel characteristics between peripheral and CNS capillaries and postcapillary venules.

<table>
<thead>
<tr>
<th>Cell types</th>
<th>Periphery</th>
<th>CNS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Capillaries</td>
<td>Postcapillary venules</td>
</tr>
<tr>
<td>Pericytes</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Astrocytic endfeet</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Adhesion molecules</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>TJs</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Paracellular diffusion of water soluble molecules</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pinocytotic transport of water soluble molecules</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Vesicular activity</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

^aDepending on organ: continuous (e.g. lung), fenestrated (e.g. kidney glomeruli), sinusoid (e.g. liver).
transporters, restrict uncontrolled paracellular and transcellular diffusion of hydrophilic molecules across the BBB endothelium (15).

The unique barrier characteristics of BBB endothelial cells are not intrinsic but rely on the cross-talk with cellular and acellular elements at the level of CNS microvessels, commonly referred to as the neurovascular unit (NVU) (15). On their abluminal side, high numbers of pericytes are embedded in the endothelial basement membrane hereby forming a continuous, non-overlapping chain-like network (33). Brain microvessels have a higher pericyte coverage than peripheral microvessels. The ratio of pericytes to endothelial cells of the BBB ranges between 1:1 and 1:3, covering up to 50% of the endothelial abluminal surface (34, 35). In peripheral vascular beds the pericyte: endothelial ration was reported 1:100 (skeletal muscle) with an estimated abluminal endothelial coverage between 10 and 25% (36, 37). Pericytes form multiple synapse-like “peg-socket” contacts with the neighbouring endothelial cells suggesting a tight functional coupling of the high number of CNS pericytes with the BBB endothelium. Pericytes have indeed been shown to inhibit vesicular activity of BBB endothelial cells and thus limit BBB transcellular permeability (38). This may prohibit availability of vesicular stores of chemokines or other diffusible trafficking cues available in peripheral vascular beds (39) and thus contribute to the unique mechanisms involved in immune cell extravasation across the BBB.

Unlike microvessels in other tissues, parenchymal CNS microvessels are ensheathed by a second barrier, referred to as the glia limitans (Fig. 1). It is composed of polarized astrocytes, which enclose with their foot processes the abluminal aspect of parenchymal CNS microvessels and deposit a second basement membrane, the parenchymal basement membrane, thus ultimately shielding the CNS parenchyma from the vascular space (5). Astrocytes contribute to BBB maturation and maintenance via sonic hedgehog and Wnt signaling pathways (40). At the surface of the brain and spinal cord namely at the level of the leptomeninges, below the pia mater, the glia limitans perivascularis continues as glia limitans superficialis and thus covers the entire surface of the brain and spinal cord parenchyma (41) (Fig. 1). Hence, it is the glia limitans that establishes an additional border towards the CNS parenchyma, where CNS-resident cells such as microglia, oligodendrocytes and neurons are localized. At the level of the CNS capillaries, the endothelial basement membrane and the glia limitans perivascularis are in intimate association while at the level of postcapillary venules a separation between the endothelial and parenchymal basement membrane can be visualized especially in neuroinflammation (Fig. 1). This perivascular space is considered to connect to cerebrospinal fluid (CSF)-filled Virchow–Robin spaces, which harbour conventional antigen-presenting cells such as dendritic cells (42).

It is important to note that in addition to the BBB established by parenchymal CNS microvascular endothelial cells, a functional BBB can also be found at the level of the venules in the subpial and subarachnoid space (SAS) (43), despite the fact that these venules lack direct ensheathment with astrocyte endfeet. Indeed, the CSF-filled SAS is bordered by the arachnoid barrier towards the dura mater and the skull and by the glia limitans superficialis towards the CNS parenchyma (Fig. 1). Therefore, blood vessels in the SAS are not ensheathed by a second basement membrane and rather form a direct barrier between the blood and the CSF in the SAS. Nevertheless, these vessels retain BBB features and represent an important entry point for immune cells into the CNS (43) (reviewed in (9)). In addition, BBB endothelial cells in the SAS and in CNS parenchyma differ in the expression of key adhesion molecules, with important implications for immune cell trafficking into these two compartments. Resembling peripheral vascular endothelial cells, leptomeningeal endothelial cells constitutively express and store P-selectin in their Weibel–Palade bodies, which upon an inflammatory stimulus can be readily exposed on their surface and contribute to immune cell recruitment (44). In contrast, CNS parenchymal endothelial cells lack constitutive expression of P-selectin, which requires de novo transcription upon an inflammatory stimulus, underscoring the active role of the BBB in controlling immune cell trafficking into the CNS (45). Microvessels in the most outer layer of the meninges, the dura mater, do not form a BBB and are not addressed here as they are also separated from the CNS by the arachnoid barrier forming a meningeal blood-CSF barrier (5).

Methodological approaches to investigate immune cell trafficking across the BBB

In vitro and in vivo imaging approaches aiming to investigate immune cell trafficking across the BBB are confronted (i) with the challenges of the unique features of BBB endothelial cells, relying on continuous crosstalk with the elements of the NVU and (ii) the complex CNS anatomy and thus limited accessibility for imaging. Meaningful modelling of immune cell trafficking across the BBB...
in vitro requires reliable culture models that truthfully maintain BBB characteristics. Higher numbers of T cells are seen to cross a monolayer of immortalized mouse brain endothelioma bEnd5 cells, which fail to establish mature TJS, when compared to a monolayer of primary mouse brain microvascular endothelial cells, which retain excellent BBB features during 1 week in culture (46). In the presence of shear flow this in vitro BBB model allows to investigate extended T-cell crawling against the direction of flow, searching for rare sites permissive for diapedesis (47), a unique T cell behaviour on the BBB observed by in vivo imaging studies (48, 49). Thus, identification of the molecular mechanisms mediating the multi-step migration of immune cells across the BBB in vitro requires stringent endothelial barrier models best to be combined with sophisticated microfluidics and live cell imaging.

On the other hand, in vivo imaging approaches require complicated surgery preparations for cranial or spinal cord windows allowing to access the brain grey matter and spinal cord white matter tissue for the available intravitral microscopy techniques (50, 51, 52). Depending on the intravitral microscopy technology used,
Figure 2

Multi-step T-cell extravasation across the BBB during health and neuroinflammation. T-cell extravasation across subarachnoid venules during immune surveillance (A) or across BBB postcapillary venules during inflammation (B) is depicted. Leptomeningeal endothelial cells store P-selectin in Weibel-Palade bodies, however, in the absence of inflammation, α4β1-mediated capture is the most observed first interaction. After GPCR-mediated shear-

https://vb.bioscientifica.com
https://doi.org/10.1530/VB-19-0033
© 2020 The authors
Published by Bioscientifica Ltd
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Downloaded from Bioscientifica.com at 12/09/2022 12:16:29PM via free access
Imaging penetration is limited to the leptomeningeal or subpial spaces. The current lack of fluorescent reporter mice allowing to precisely identify the arachnoid barrier and glia limitans impede precise localization of superficial CNS microvessels to the subpial or SAS, especially as in the mouse the SAS spans only about 30–50 μm in healthy conditions. When performing two-photon intravital microscopy (2P-IVM), second harmonic generation signals generated by collagen type I in the dura mater and in the subpial space might provide some orientation (summarized in (10)). The lack of precise landmarks for imaging the brain barriers while following immune cell trafficking across the BBB in vivo presently hampers delineation of the different mechanisms mediating immune cell trafficking across the BBB in the SAS versus the CNS parenchyma.

Immune cell migration across the BBB during immune surveillance

The BBB allows for immune cell trafficking into the CNS in the absence of neuroinflammation but strictly limits CNS entry to immune cell subsets required for immune surveillance and detected in the CSF (53, 54) (Fig. 2A). The molecular mechanisms involved in the multi-step immune cell trafficking across the BBB are summarized in Table 3. The few studies that have investigated immune cell migration across the BBB during immune surveillance by intravital microscopy have mostly focused on effector/memory CD4+ T cells in the context of experimental autoimmune encephalomyelitis (EAE), a CD4+ T-cell mediated animal model of multiple sclerosis (48, 55, 56). EAE is an autoimmune disease of the CNS, which can be induced by injection of CNS myelin antigens emulsified in complete Freund’s adjuvant (57), or by adoptive transfer of CNS autoantigen-specific CD4+ T cells into syngeneic naïve recipients of susceptible rodent strains (58), with the former often referred as active EAE (aEAE) and the latter as transfer EAE (tEAE). The interaction of encephalitogenic CD4+ Th1 cells with the spinal cord microvasculature was found to be unique due to the lack of rolling and a prominent role of α4 integrin - vascular cell adhesion protein-1 (VCAM-1) interaction in mediating capture and sustained arrest of these T cells to spinal cord venules (55) (Fig. 2). Th1 cell diapedesis across the non-inflamed spinal cord postcapillary venules is mediated by leukocyte function-associated antigen-1 (LFA-1, αβ2 integrin) and its ligand intercellular adhesion molecule 1 (ICAM-1) (59) (Fig. 2A). GPCR signaling is prerequisite for sustained T-cell adhesion on the BBB (55); however, the chemokines or lipid mediators involved in this step remain to be determined. Mouse and human BBB endothelial cells constitutively express CCL19 (60, 61), which binds CCR7 and was therefore suggested to mediate the migration of circulating CCR7 expressing central memory T cells across the BBB as 90% of T cells in the CSF express CCR7 (62). Direct evidence for endothelial CCL19 in mediating T-cell trafficking to the CNS in the absence of neuroinflammation is however lacking.

The migration of activated CD4+ T cells across the BBB was shown in rodent animal models to be independent of antigen recognition on the CNS endothelial cells (55, 48, 51, 63, 64, 65). In contrast, antigen recognition on perivascular or leptomeningeal APCs is necessary for subsequent T-cell migration across the glia limitans and infiltration into the CNS parenchyma (48, 66, 67) (Fig. 2). CD4+ T cells localized in the SAS can crawl along not further defined scaffolds and be eventually washed away by the movement of the CSF to reach other CSF compartments in the CNS (5, 56). Interestingly, intrinsic characteristics of the leptomeningeal BBB predispose the leptomeningeal compartment as preferred site for T-cell immunosurveillance. Indeed, diapedesis of fluorescently labelled activated CD4+ T cells across parenchymal BBB endothelial cells was only observed 4–6 hours after injection (59), while accumulation in leptomeningeal spaces was already observed 2 h after injection (68).

Figure 2 Continued
resistant arrest, T cells crawl against the direction of the flow and cross the BBB endothelium preferentially via the paracellular pathway. Pial cells are reported to partially cover the venular wall in the SAS (highlighted by the question mark), but do not seem to establish a barrier for T cell extravasation. In the absence of CNS antigens presented by subarachnoid macrophages and dendritic cells on MHC-II molecules, T cells will not cross the glia limitans and may rather be flushed away with the CSF. During inflammation, leptomeningeal but also parenchymal BBB endothelial cells (8) allow for activated T-cell rolling, mediated by P-selectin which is de novo expressed as it is not stored in Weibel-Palade bodies. Inflammatory chemokines produced by astrocytes are transported from the abluminal to the luminal side of the BBB by ACRK1. After their GPCR-dependent arrest, T cells crawl on endothelial ICAM-1 and ICAM-2 against the direction of the flow with increased levels of endothelial ICAM-1 leading to increased transcellular T cell diapedesis. Once T cells have crossed the BBB endothelium (1), CNS-antigen-specific T cells may recognize their cognate antigens on perivascular APCs (2) and become reactivated behind the BBB. Matrix metalloproteinasises produced by infiltrating and perivascular-activated myeloid cells as well as astrocytes cleave the astrocytic endfeet from the parenchymal basement membrane, allowing for T-cell passage, a process guided by proinflammatory chemokines produced by astrocytes. Once in the CNS parenchyma, T cells induce CNS damage and manifestation of clinical disease symptoms (3). Drawings of the individual cell types were adapted from Servier Medical Art (http://smart.servier.com/), licensed under a Creative Commons Attribution 3.0 Generic License.
**Table 3**  Endothelial adhesion and signaling molecules involved in multi-step immune cell trafficking across the blood-brain barrier.

<table>
<thead>
<tr>
<th>Interaction step/molecule</th>
<th>Ligand and immune cell subset</th>
<th>Observation</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capture</strong></td>
<td></td>
<td><strong>In vivo</strong> imaging of mouse spinal cord microvessels in the absence of neuroinflammation</td>
<td>(55)</td>
</tr>
<tr>
<td>VCAM-1</td>
<td>α4β1-integrin-encephalitogenic T cells</td>
<td><strong>In vivo</strong> imaging of mouse spinal cord microvessels in the absence of neuroinflammation</td>
<td></td>
</tr>
<tr>
<td>Rolling</td>
<td></td>
<td><strong>In vivo</strong> imaging of inflamed superficial mouse brain and spinal cord microvessels during EAE</td>
<td>(73)</td>
</tr>
<tr>
<td>E/P-selectin</td>
<td>PSGL-1- encephalitogenic T cells</td>
<td><strong>In vivo</strong> imaging of superficial mouse brain microvessels in neuroinflammation</td>
<td>(71)</td>
</tr>
<tr>
<td>E/P-selectin</td>
<td>PSGL-1- CD8 T cells from MS patients</td>
<td><strong>In vivo</strong> imaging of superficial mouse brain microvessels in neuroinflammation</td>
<td>(70)</td>
</tr>
<tr>
<td>P-selectin and α4-integrin</td>
<td>Endogenous leukocytes</td>
<td><strong>In vivo</strong> imaging of superficial mouse brain microvessels in neuroinflammation</td>
<td>(143)</td>
</tr>
<tr>
<td><strong>Integrin activation</strong></td>
<td></td>
<td><strong>ACKR1</strong> shuttles inflammatory chemokines from the CNS to the luminal side of the BBB - mice lacking vascular</td>
<td>(74)</td>
</tr>
<tr>
<td>ACKR1</td>
<td>CNS infiltrating cells</td>
<td>ACKR1 develop ameliorated EAE</td>
<td></td>
</tr>
<tr>
<td><strong>Arrest and adhesion</strong></td>
<td></td>
<td><strong>In vivo</strong> imaging of T-cell interaction with rat and mouse spinal cord microvessels in the absence and presence</td>
<td>(47, 55, 144)</td>
</tr>
<tr>
<td>VCAM-1</td>
<td>Rodent encephalitogenic T cells and human T cells - α4β1-integrin (VLA-4)</td>
<td>of neuroinflammation; <strong>in vitro</strong> imaging of T-cell interaction with mouse models of the BBB under physiological</td>
<td></td>
</tr>
<tr>
<td></td>
<td>α4-integrin on CD8 T cells</td>
<td>flow <strong>In vitro</strong> adhesion and transmigration assays; CD8 T cell mediated encephalitis is inhibited by α4-integrin</td>
<td>(27, 145)</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>Activated rodent CD4 and CD8 T cells</td>
<td>Function blocking antibodies</td>
<td>(94, 106)</td>
</tr>
<tr>
<td>ICAM-2</td>
<td>Activated rodent CD4 and CD8 T cells</td>
<td><strong>In vivo</strong> imaging of T cell and neutrophil interaction with mouse models of the BBB under physiological flow</td>
<td>(47, 94, 106)</td>
</tr>
<tr>
<td></td>
<td>α4β1-integrin expressing DCs</td>
<td><strong>In vivo</strong> imaging of mouse spinal cord microvessels and <strong>in vivo</strong> homing studies in the context of</td>
<td>(124, 125, 126)</td>
</tr>
<tr>
<td><strong>Polarization</strong></td>
<td></td>
<td><strong>In vitro</strong> imaging of T cell interaction with mouse models of the BBB under physiological flow</td>
<td>(47)</td>
</tr>
<tr>
<td>ICAM-1</td>
<td></td>
<td><strong>In vitro</strong> imaging of T cell interaction with mouse models of the BBB under physiological flow</td>
<td>(47)</td>
</tr>
<tr>
<td>ICAM-2</td>
<td></td>
<td><strong>In vitro</strong> imaging of T cell interaction with mouse models of the BBB under physiological flow</td>
<td>(47)</td>
</tr>
<tr>
<td><strong>Extended crawling against the direction of blood flow</strong></td>
<td><strong>In vitro</strong> imaging of T cell interaction with mouse models of the BBB under physiological flow</td>
<td>(47)</td>
<td></td>
</tr>
<tr>
<td>ICAM-1</td>
<td></td>
<td>(47)</td>
<td>(47)</td>
</tr>
<tr>
<td>ICAM-2</td>
<td></td>
<td>(47)</td>
<td>(47)</td>
</tr>
<tr>
<td>Ninjurin?</td>
<td>Encephalitogenic T cells · ninjurin</td>
<td><strong>In vivo</strong> imaging of encephalitogenic T cells interacting with the rat spinal cord microvasculature at onset of EAE</td>
<td>(146)</td>
</tr>
<tr>
<td></td>
<td>Encephalitogenic T cells · α4β1-integrin VLA-4</td>
<td><strong>In vivo</strong> imaging of encephalitogenic T cells interacting with the rat spinal cord microvasculature at onset of EAE</td>
<td>(146)</td>
</tr>
<tr>
<td><strong>Diapedesis</strong></td>
<td></td>
<td>Blocking CD99 affects immune cell migration across but not adhesion to human BBB models under static conditions;</td>
<td>(93, 147)</td>
</tr>
<tr>
<td>CD99</td>
<td>Probably CD99 on immune cells</td>
<td>CD99 blockade ameliorates EAE in the mouse inhibition of Gai signalling in T cells blocks diapedesis but not prior polarization or crawling on <strong>in vitro</strong> BBB models under flow</td>
<td></td>
</tr>
<tr>
<td>GPCR ligands</td>
<td>Pertussis toxin sensitive GPCRs on T cells</td>
<td>**Inhibition of Gai signalling in T cells blocks diapedesis but not prior polarization or crawling on <strong>in vitro</strong> BBB models under flow</td>
<td>(94)</td>
</tr>
<tr>
<td>Caveolin-1</td>
<td>Encephalitogenic Th1 cells</td>
<td>Lack of endothelial caveolin 1 reduces transcellular diapedesis of Th1 cells into the CNS in EAE</td>
<td>(90)</td>
</tr>
<tr>
<td>CXCL12</td>
<td>CXCR4+ T cells, B cells and monocytes</td>
<td>Function blocking of CXCR4 interferes with the diapedesis of T cells, B cells and monocytes across a rodent model of the BBB under physiological flow</td>
<td>(119)</td>
</tr>
</tbody>
</table>

(Continued)
Immune cell trafficking across the BBB in neuroinflammation

During neuroinflammation, the BBB endothelium undergoes changes including increased expression of adhesion molecules, proinflammatory cytokines and chemokines combined with reduced expression of junctional molecules, setting the stage for increased recruitment of circulating leukocytes across the BBB (summarized in (9, 37, 40)).

CD4+ and CD8+ T cells

Once an inflammatory stimulus perturbs the CNS parenchymal microvasculature, upregulation of P-selectin allows for T-cell rolling, a process mediated by the interaction between P-selectin glycoprotein ligand 1 (PSGL-1) on the T cells and E/P-selectin on the endothelial cells (69, 70, 71) (Fig. 2B). During rolling, T cells reduce their speed, from ~1000 μm/s to 5–10 μm/s (72, 73). Paradoxically, despite their essential role in T-cell rolling on the BBB, absence of PSGL-1 and/or E/P-selectin in mice fails to reduce T-cell entry into the CNS and thus amelioration of EAE, suggesting that T-cell rolling is not required for T-cell migration across the inflamed BBB (71). In fact intravital microscopy studies have shown that a low number of T cells can eventually arrest in inflamed spinal cord vessels of E/P-selectin-deficient mice (71), subsequently allowing for their diapedesis across the BBB and initiation of EAE.

T cells do require GPCR signalling to firmly arrest on the BBB (73). However, the endothelial chemokines or lipid mediators triggering T cell arrest on the BBB are a matter of debate. In this context it is interesting to note that the atypical chemokine receptor 1 (ACKR1) is upregulated on the BBB during EAE and in MS (74). ACKR1 shuttles inflammatory chemokines produced for example, by astrocytes in neuroinflammatory conditions...
from the abluminal to the luminal side of the BBB (Fig. 2B) and lack of vascular ACKR1 ameliorates clinical signs of EAE in C57BL/6 mice (74). ACKR1-mediated chemokine shuttling may thus lead to the presence of a variety of CNS produced proinflammatory chemokines on the luminal side of the BBB.

GPCR signaling leads to inside-out-activation of integrins mediating the firm arrest of T cells on the luminal surface of the inflamed BBB endothelial cells. This crucial step is mediated by the integrins LFA-1 and very late antigen-4 (VLA-4, α4β1, integrin) and their endothelial ligands, ICAM-1 and VCAM-1, respectively (47, 75, 76, 77, 78) (Fig. 2B). EAE studies have ruled out the involvement of integrin α4β1 in T-cell arrest on the BBB (79, 80, 81), while recent evidence has suggested a specific role for α4β7 integrin in Th17 cell-mediated EAE pathology in mice (82). The crucial role played by α4β1/VCAM-1 interaction in T-cell arrest on the BBB is highlighted by the fact that blocking α4-integrins has been translated into the most effective treatment for relapsing-remitting MS with the humanized monoclonal anti-α4 integrin antibody natalizumab. In addition to VCAM-1, another endothelial ligand for α4β1 integrin, namely JAM-B has been shown to be involved in CDB4+ (27), but not CD4+ (24) T-cell migration across the BBB in mouse models.

After arrest, T cells polarize and start to crawl in search for sites permissive for diapedesis across the BBB endothelium (Fig. 2B). In vitro (47) and in vivo (48) rodent studies have shown that barrier properties of the BBB translate to post-arrest extended crawling of CD4+ T cells on BBB endothelial cells, preferentially against the direction of the blood flow, searching for rare sites permissive for diapedesis (47, 83). It has been shown before that activated T cells but not neutrophils crawl against the direction of the flow on ICAM-1-coated surfaces (84). This underscores that in addition to molecular cues, shear stress impacts on directionality of T cell crawling. In fact, lack of endothelial ICAM-1 and ICAM-2 on a mouse model of the BBB, abrogates Th1 cell polarization and crawling (47, 83) supporting the notion that endothelial ICAM-1 and ICAM-2 are essential for mediating the Th1 cell crawling against the direction of flow on the BBB with no additional role of α4β1/VCAM-1 (47, 83). Side-by-side comparison of mouse encephalitogenic Th1 and Th17 cell interaction with the BBB has shown that Th1 cells, in comparison to Th17 cells, arrest in higher numbers on the BBB in vitro and in vivo, however, both Th1 and Th17 cells rely on endothelial ICAM-1 and ICAM-2 for crawling on the BBB (49). Interestingly, genetic ablation of α4 integrins in mouse T cells blocks Th1 cell entry into the CNS during EAE, while Th17 cells can still accumulate in the brain but not the spinal cord using LFA-1 (85, 86). These observations suggest that Natalizumab rather blocks Th1 and Th17 cell entry into the spinal cord but only Th1 cell entry into the brain in MS (9).

Barrier characteristics of the BBB endothelium not only result in extended crawling of CD4+ T cells but ultimately in differences in their diapedesis. In peripheral vascular beds upon their arrest T cells crawl for short distances and promptly cross the endothelium through the endothelial junctions, a process known as paracellular diapedesis (3). Paracellular immune cell diapedesis is envisioned in a zipper-like fashion where the immune cell transiently replaces the endothelial cell adhesive connections visible as remodeling of the endothelial cell junctions (87, 88).

In accordance to the presence of complex and continuous TJ beds, T-cell diapedesis across the inflamed BBB has rather been observed to occur via a transcellular pathway, where the T cells form a pore through the endothelium and leave the complex TJ morphology intact (9, 32, 89). However, a recent study found that Th1 but not Th17 cells rely on caveolin-1 for transcellular diapedesis in a mouse BBB in vitro model (90) suggesting that Th17 cells can cross the BBB via a paracellular pathway. The molecular mechanisms directing paracellular versus transcellular T cell diapedesis across the BBB are not yet understood.

Live cell imaging studies exploring Th1-cell diapedesis across in vitro mouse models of the BBB under physiological flow have shown that low versus high cell surface levels of endothelial ICAM-1 direct Th1 cells to paracellular versus transcellular sites of diapedesis across the BBB, respectively (83). These findings are in accordance to the previous observations of the increased transcellular T-cell diapedesis across the BBB during neuroinflammation, when endothelial ICAM-1 levels are high. Paracellular T-cell diapedesis across the inflamed BBB in mice was proposed to be facilitated by claudin-5 extracellular vesicles released from BBB endothelial cells that decorate the T cells, thus allowing to squeeze through BBB TJMs in a zipper-like fashion (91). On the other hand BBB breakdown accompanied with impaired BBB junctional integrity does not correlate with increased paracellular T-cell diapedesis, underscoring that vascular permeability and cellular pathways of T-cell diapedesis across the BBB are regulated by different mechanisms. In fact, increased paracellular permeability of the BBB due to the lack of endothelial PECAM-1 (92) or mediated by
pro-inflammatory cytokine stimulation does not correlate with increased paracellular but rather transcellular Th1 cell diapedesis across the mouse BBB under flow in vitro (83, 93). Irrespective of the cellular pathway of T-cell diapedesis across the BBB, inhibition of GPCR signalling in both, CD4+ and CD8+ T cells completely abrogates their diapedesis across the mouse BBB (94). These observations underscore that the BBB actively controls the cellular and molecular mechanisms of T-cell diapedesis and that intact cell-to-cell junctions are required to direct T cells to paracellular sites for diapedesis across the BBB.

T cells that have successfully crossed the BBB have not yet reached the CNS parenchyma proper but rather the CSF drained perivascular or subarachnoid space. To enter the CNS parenchyma the T cells must cross a second barrier, the glia limitans (41) (Fig. 2). Deposition of laminin α5 and α6 in the endothelial basement membrane allows it to be distinguished from the parenchymal basement membrane of the glia limitans, which is constituted by laminin α1 and α2 (95). Effector CD4+ T cells do not bind to laminin α1 and α2 (96), and their crossing of the glia limitans in neuroinflammation is rather mediated by matrix metalloproteinases (MMPs), specifically the gelatinases MMP-2 and MMP-9 (97). MMP-2 and MMP-9 cleave β-dystroglycan, an extracellular matrix receptor of astrocyte endfeet (97) and modulate chemokine activities in the perivascular space and SAS (98), allowing for T cell crossing the glia limitans and entering the CNS parenchyma (Fig. 2B). In EAE clinical disease starts, when immune cells cross the glia limitans (97).

B-cells

Due to the difficulty of isolating and maintaining B cells in culture there are only few studies that have addressed B-cell migration across the BBB. Migration of human B cells across a human BBB model was found to be mediated by endothelial ICAM-1 but not endothelial VCAM-1 (99). As blocking αβ1-integrins was found to decrease B-cell migration across the BBB, alternative αβ1-integrin ligands, that is, fibronectin of JAM-B may contribute to B-cell migration across the BBB (99). Additionally, blocking chemokines produced by these BBB endothelial cells such as CCL2 and CXCL8 resulted in reduced B-cell diapedesis. Moreover, a recent study demonstrated that the activated leukocyte cell adhesion molecule (ALCAM) participates in the migration of human B cells across the inflamed BBB, and blocking ALCAM ameliorated clinical signs of a B-cell-dependent EAE model, supporting its role in B cell entry into the CNS (100).

Innate immune cells

The immune privilege of the CNS extends to innate immunity. Indeed, inflammatory responses initiated by pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs) caused by injection of bacterial products (101), chemokines, cytokines (102) or induced cell death in the murine CNS parenchyma (103, 104), respectively, do not elicit rapid infiltration of neutrophils or monocytes as observed during a response to such stimuli in peripheral organs (summarized in (105)). This suggests that barrier characteristics of the BBB extend to an even stricter control of innate immune cell entry into the CNS.

Neutrophils

The migration of neutrophils across the BBB has been studied in the context of acute non-sterile and sterile inflammation such as bacterial meningitis and ischemic stroke. Mimicking bacterial infection by stimulation of an in vitro model of the mouse BBB with LPS we have found by means of in vitro live cell imaging that GPCR-dependent activation of αβ2 and αβ3 integrins allows for neutrophil interaction with endothelial ICAM-1, resulting in neutrophil arrest and polarization, respectively (106). Neutrophil crawling and preferential paracellular over transcellular diapedesis across the primary mouse brain microvascular endothelial cells was dependent on ICAM-1 and ICAM-2 and both β2 integrins. This seems to be in accordance to previous observations showing that upon αβ2 (LFA-1)-mediated arrest neutrophils crawl using αMβ2 (Mac-1)- integrin on endothelial ICAM-1 to sites permissive for diapedesis in inflamed mouse cremaster microvessels (107). Interestingly, lack of ICAM-1 and ICAM-2 on mouse brain microvascular endothelial cells abrogated transcellular but not paracellular neutrophil diapedesis across the BBB, suggesting a role of β2 integrins in this diapedesis pathway (106). Employing a mouse in vitro BBB model and a microfluidic chamber we found that the ischemic BBB does not support neutrophil migration across the barrier (106). Neutrophils do however accumulate in the brain after ischemic stroke and are considered the main cause of reperfusion injury. The molecular mechanisms involved in their potential recruitment into the CNS after ischemic stroke are a matter of debate.

Generally, neutrophil rolling on the vascular wall has been described to be dependent on P-selectin (108); however, a mouse model of cerebral ischemia excluded
a role of the P-selectin ligand PSGL-1, in neutrophil accumulation in the CNS (109). Previous studies of ischemic stroke in ICAM-1-deficient mice, which still express soluble ICAM-1 splice variants, have proposed endothelial ICAM-1 to be involved in neutrophil interaction with the BBB (110, 111). In contrast, similar studies performed in ICAM-1null mice have not confirmed this observation (112). Additional studies have proposed a role for α4β1 integrins in neutrophil recruitment to the CNS after stroke (113), however, inhibition of α4 integrins by natalizumab infusion failed to ameliorate acute ischemic stroke in humans in a Phase II2b trial (summarized in (105)) and blocking the endothelial α4β1-integrin ligand VCAM-1 in experimental stroke models did not ameliorate brain damage (114). We and others have observed that after ischemic stroke in experimental mouse models but also in humans, neutrophils accumulate within the confines of the nervous system and in the SAS (115, 116) rather than reaching the CNS parenchyma. This suggests that in addition to the BBB, the glia limitans provides a not yet considered barrier for neutrophil entry into the CNS.

**Monocytes and dendritic cells**

Monocyte migration across the BBB has been investigated in different contexts, ranging from CNS virus infections to EAE and MS. Different molecular mechanisms have been observed in monocyte migration across the BBB as compared to those for T cells and neutrophils. For instance, blocking ninjurin-1 reduced adhesion and migration of monocytes, but not T and B cells, across a human in vitro model of the BBB (117). Furthermore ALCAM, was identified to mediate rolling, adhesion and diapedesis of human CD14+ monocytes but not of human Th1 cells on a human BBB model (118). A comparative study analyzed the role of CXCL12 by blockage of its receptor CXCR4 in human CD4+, CD8+, CD19+ B cells and CD14+ monocytes migration under flow across the human brain microvasculature. Surprisingly, monocyte but not T-cell migration across the BBB was significantly reduced by blockage of CXCR4 (119). In addition, monocytes may directly activate the BBB endothelium, as co-culture of monocytes with rat brain endothelium triggered the release of tissue-type plasminogen activator from the brain endothelial cells, leading to loss of junctional occludin and increased monocytes diapedesis across the BBB endothelium (120). Interestingly, CD14+ CD16+ monocytes isolated from HIV-infected patients have increased expression of JAM-A and ALCAM, and both molecules participate in CD14+ CD16+ monocyte migration across the BBB (121), as well as CXCR7 (122). On the other hand, Zika virus-infected monocytes depend on CCR7 and receptor for advanced glycation end (RAGE) for transmigration across the human BBB (123).

Few studies have investigated the migration of dendritic cells (DC) across the BBB. In vivo live cell imaging of the spinal cord microvasculature during EAE in mice demonstrated a prominent involvement of α4β1 integrins in mediating DC arrest in inflamed spinal cord microvessels (124). A crucial role of α4β1-integrins for CNS entry was recently also confirmed for mouse plasmacytoid DCs (125) as well as monocyte-derived DCs (126). Interestingly, steady-state migration of conventional and plasmacytoid DCs was found to be independent of α4 integrins (126), suggesting α4-integrin-mediated DC migration across the BBB to be a mechanism restricted to neuroinflammatory conditions. On the other hand it was shown that myeloid cells do not rely on β1-integrins to infiltrate the CNS during EAE in mice (127), underscoring that myeloid cells may use pleiotropic mechanisms to cross the BBB.

**Concluding remarks**

The endothelial BBB strictly controls immune cell entry into the CNS in the absence and presence of neuroinflammation. CNS immune surveillance is ensured by restricting access of limited immune cells to the CSF drained compartments of the CNS bordered by the glia limitans. In conditions of neuroinflammation the barrier properties of the BBB are impaired and allow for increased but not entirely uncontrolled immune cell entry into the CNS. Changes in the perivascular space and SAS chemokine environment combined with impairment of the glia limitans eventually allows for immune cell infiltration into the CNS parenchyma, leading to defective CNS function and thus clinical signs of disease. A deeper understanding of the specific molecular mechanisms used by the different immune cell subsets to cross the BBB would allow for improving therapeutic targeting of immune cell subsets potentially harmful for the CNS while leaving CNS immune surveillance largely unaffected. Also, as outlined in this review, the vast majority of the studies on immune cell trafficking across the BBB have focused on inflammatory or disease conditions, while knowledge on immune cell entry into the CNS during homeostasis is still scarce and requires further investigations.
Declarations of Interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by Swiss National Foundation grant 31003A_3170131, the EU Horizon 2020 grant ‘BRAIN’ H2020-MSCA-ITN-2015 675619, the Swiss universities PhD Program Cell Migration and the Microcopy Imaging Center of the University of Bern.

References


37 Daneman R & Pratt A. The blood-brain barrier. *Cold Spring Harbor Perspectives in Biology* 2015 7 a020412. (https://doi.org/10.1101/cshperspect.a020412)


42 Mundt S, Mrdjen D, Utz SG, Greter M, Schreiner B & Becher B. Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation. *Science Immunology* 2019 4 eaau8380. (https://doi.org/10.1126/sciimmunol.aau8380)


46 Steiner O, Coisne C, Engelhardt B & Lyck R. Comparison of immunized B6D2F1 and primary mouse brain microvascular endothelial cells as in vitro blood-brain barrier models for the study of T cell extravasation. *Journal of Cerebral Blood Flow and Metabolism* 2011 31 315–327. (https://doi.org/10.1038/jcbfm.2010.96)


Alt C, Laschinger M & Engelhardt B. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. European Journal of Immunology 2002 32 2123–2144. (https://doi.org/10.1002/eji.200231823)


Rothhammer V, Heinik S, Petermann F, Strivastava R, Clausen MC, Hemmer B & Korn T. Th17 lymphocytes traffic to the central nervous


102 Anderson PB, Perry VH & Gordon S. Intracerebral injection of proinflammatory cytokines or leucocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. *Journal of Immunology* 1992 176 255–259. (https://doi.org/10.4049/jimmunol.176.1.255)


106 Gorina R, Lyck R, Vestweber D & Engelhardt B. beta2 integrin-mediated crawling on endothelial ICAM-1 and ICAM-2 is a prerequisite for transcellular neutrophil diapedesis across the inflamed blood-brain barrier. *Journal of Immunology* 2014 192 324–337. (https://doi.org/10.4049/jimmunol.1300858)


138 Hawkins BT & Davis TP. The blood-brain barrier/neurovascular unit as a selective barrier to polymorphonuclear leukocytes in health and disease. *Pharmacological Reviews* 2005 57 173–185. (https://doi.org/10.1124/pr.57.2.4)


143 Kerfoot SM & Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. *Journal of Immunology* 2002 169 1000–1006. (https://doi.org/10.4049/jimmunol.169.2.1000)

144 Coisine C, Mao W & Engelhardt B. Cutting edge: natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain
barrier in vivo in an animal model of multiple sclerosis. *Journal of Immunology* 2009 182 5909–5913. ([https://doi.org/10.4049/jimmunol.0803418](https://doi.org/10.4049/jimmunol.0803418))


Received in final form 12 March 2020
Accepted 20 March 2020
Accepted Manuscript published online 20 March 2020